Unlike tech investing, where a single power-law outlier can return the entire fund, biotech wins are smaller in magnitude. This dynamic forces biotech VCs to prioritize a higher success rate across their portfolio rather than solely hunting for one massive unicorn.

The memo details how investors rationalize enormous funding rounds for pre-product startups. By focusing on a colossal potential outcome (e.g., a $1 trillion valuation) and assuming even a minuscule probability (e.g., 0.1%), the calculated expected value can justify the investment, compelling participation despite the overwhelming odds of failure.

Startups with legal claims as assets can sell portions of their cases to litigation finance firms. This provides immediate, non-dilutive capital to fund operations, de-risking the business model while waiting for lengthy legal proceedings to conclude.

Apogee built its strategy around known biological mechanisms, focusing innovation solely on antibody engineering. This allowed them to de-risk assets early and efficiently (e.g., proving half-life in healthy volunteers). This clear, stepwise reduction of risk proved highly attractive to capital markets, enabling them to raise significant funds for late-stage development.

Drug development can take a decade, a timeframe that misaligns with typical investor horizons and employee careers. Success requires navigating fluctuating capital market cycles and implementing strategies to retain key scientific talent for the long haul.

Afeyan distinguishes risk (known probabilities) from uncertainty (unknown probabilities). Since breakthrough innovation deals with the unknown, traditional risk/reward models fail. The correct strategy is not to mitigate risk but to pursue multiple, diverse options to navigate uncertainty.

The path for biotech entrepreneurs is a long slog requiring immense conviction. Success ("liftoff") isn't just a clinical trial result, but achieving self-sustaining profitability and growth. This high bar means founders may need to persevere through years of market indifference and financing challenges.

The company intentionally makes its early research "harder in the short term" by using complex, long-term animal models. This counterintuitive strategy is designed to generate highly predictive data early, thereby reducing the massive financial risk and high failure rate of the later-stage clinical trials.

Post-IPO, credibility is a biotech's most valuable asset. Leaders should "under-promise and over-perform" by avoiding specific quarterly guidance for clinical milestones. Instead, use broader windows like "first half of the year" to build in flexibility, as clinical trials rarely run on a perfect schedule.